Amgen (AMGN) Reiterated Outperform at BMO Capital After Phase 1 Data at ESMO
Tweet Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $240.00 price target on Amgen (NASDAQ: AMGN) after Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
